Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03783403
Recruitment Status : Recruiting
First Posted : December 21, 2018
Last Update Posted : October 25, 2021
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 8, 2022
Estimated Study Completion Date : November 7, 2024